NCT05676749 - C-TIL051 in Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

August 31, 2027

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

C-TIL051

C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab

Trial Locations (4)

RECRUITING

Allegheny Health Network-West Penn Hospital, Pittsburgh

RECRUITING

Duke Center for Cancer Immunotherapy, Raleigh

RECRUITING

Ochsner MD Anderson Cancer Center, New Orleans

WITHDRAWN

UC San Diego Moores Cancer Center, La Jolla